Belhassen-Garcia Moncef, Rábano-Gutiérrez Alberto, Velasco-Tirado Virginia, Romero-Alegria Angela, Pérez-Garcia Maria-Luisa, Martin-Oterino Jose Angel
Department of Internal Medicine, Unit of Infectious Diseases. IBSAL. University Hospital of Salamanca. CIETUS, University of Salamanca, Spain.
Intern Med. 2015;54(5):519-24. doi: 10.2169/internalmedicine.54.2748. Epub 2015 Jan 15.
Antisynthetase syndrome is a disorder belonging to the dermatomyositis/polymyositis group, with high rates of morbidity and mortality. We herein present the case of a 71-year-old man who was diagnosed with antisynthetase syndrome and treated with rituximab. Almost three years later, the patient showed right-sided hemiparesis that ultimately progressed to complete hemiplegia and advancing cognitive deterioration with a poor clinical outcome. The neuropathological diagnosis was progressive multifocal leukoencephalopathy. Treatment with rituximab for antisynthetase syndrome itself plays a fundamental role in the development of infectious complications.
抗合成酶综合征是一种属于皮肌炎/多肌炎组的疾病,发病率和死亡率很高。我们在此报告一例71岁男性患者,该患者被诊断为抗合成酶综合征并接受了利妥昔单抗治疗。大约三年后,患者出现右侧偏瘫,最终发展为完全性偏瘫,并伴有进行性认知功能减退,临床预后较差。神经病理学诊断为进行性多灶性白质脑病。利妥昔单抗治疗抗合成酶综合征本身在感染性并发症的发生中起重要作用。